Deoxycoformycin: Neurological toxicity

Pierre P. Major, Ram P. Agarwal, Donald W. Kufe

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I-II evaluation. Neurological toxicity has been a frequent and occasionally severe complication of treatment with this drug. A T-cell leukemia patient with an Ommaya reservoir was treated with DCF, and the pharmacokinetics of the drug in the cerebrospinal fluid and plasma were studied. DCF penetrates the cerebrospinal fluid and achieves levels as high as 1/10 the concurrent plasma levels. The accumulation of adenosine and deoxyadenosine in plasma, cerebrospinal fluid, and urine was monitored; the neuropharmacological effect of these metabolites is discussed.

Original languageEnglish
Pages (from-to)193-196
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume5
Issue number3
DOIs
StatePublished - Apr 1 1981
Externally publishedYes

Fingerprint

Pentostatin
Cerebrospinal fluid
Toxicity
Cerebrospinal Fluid
Plasmas
Adenosine Deaminase Inhibitors
T-Cell Leukemia
Pharmacokinetics
T-cells
Metabolites
Pharmaceutical Preparations
Adenosine
Urine
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Deoxycoformycin : Neurological toxicity. / Major, Pierre P.; Agarwal, Ram P.; Kufe, Donald W.

In: Cancer Chemotherapy and Pharmacology, Vol. 5, No. 3, 01.04.1981, p. 193-196.

Research output: Contribution to journalArticle

Major, PP, Agarwal, RP & Kufe, DW 1981, 'Deoxycoformycin: Neurological toxicity', Cancer Chemotherapy and Pharmacology, vol. 5, no. 3, pp. 193-196. https://doi.org/10.1007/BF00258479
Major, Pierre P. ; Agarwal, Ram P. ; Kufe, Donald W. / Deoxycoformycin : Neurological toxicity. In: Cancer Chemotherapy and Pharmacology. 1981 ; Vol. 5, No. 3. pp. 193-196.
@article{49807d231231441abbd514990526b11a,
title = "Deoxycoformycin: Neurological toxicity",
abstract = "Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I-II evaluation. Neurological toxicity has been a frequent and occasionally severe complication of treatment with this drug. A T-cell leukemia patient with an Ommaya reservoir was treated with DCF, and the pharmacokinetics of the drug in the cerebrospinal fluid and plasma were studied. DCF penetrates the cerebrospinal fluid and achieves levels as high as 1/10 the concurrent plasma levels. The accumulation of adenosine and deoxyadenosine in plasma, cerebrospinal fluid, and urine was monitored; the neuropharmacological effect of these metabolites is discussed.",
author = "Major, {Pierre P.} and Agarwal, {Ram P.} and Kufe, {Donald W.}",
year = "1981",
month = "4",
day = "1",
doi = "10.1007/BF00258479",
language = "English",
volume = "5",
pages = "193--196",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Deoxycoformycin

T2 - Neurological toxicity

AU - Major, Pierre P.

AU - Agarwal, Ram P.

AU - Kufe, Donald W.

PY - 1981/4/1

Y1 - 1981/4/1

N2 - Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I-II evaluation. Neurological toxicity has been a frequent and occasionally severe complication of treatment with this drug. A T-cell leukemia patient with an Ommaya reservoir was treated with DCF, and the pharmacokinetics of the drug in the cerebrospinal fluid and plasma were studied. DCF penetrates the cerebrospinal fluid and achieves levels as high as 1/10 the concurrent plasma levels. The accumulation of adenosine and deoxyadenosine in plasma, cerebrospinal fluid, and urine was monitored; the neuropharmacological effect of these metabolites is discussed.

AB - Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I-II evaluation. Neurological toxicity has been a frequent and occasionally severe complication of treatment with this drug. A T-cell leukemia patient with an Ommaya reservoir was treated with DCF, and the pharmacokinetics of the drug in the cerebrospinal fluid and plasma were studied. DCF penetrates the cerebrospinal fluid and achieves levels as high as 1/10 the concurrent plasma levels. The accumulation of adenosine and deoxyadenosine in plasma, cerebrospinal fluid, and urine was monitored; the neuropharmacological effect of these metabolites is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0019496712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019496712&partnerID=8YFLogxK

U2 - 10.1007/BF00258479

DO - 10.1007/BF00258479

M3 - Article

C2 - 6975188

AN - SCOPUS:0019496712

VL - 5

SP - 193

EP - 196

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -